JP2013525444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525444A5 JP2013525444A5 JP2013508174A JP2013508174A JP2013525444A5 JP 2013525444 A5 JP2013525444 A5 JP 2013525444A5 JP 2013508174 A JP2013508174 A JP 2013508174A JP 2013508174 A JP2013508174 A JP 2013508174A JP 2013525444 A5 JP2013525444 A5 JP 2013525444A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- humans
- treatment
- following compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 0 CCCCC1(CC)NC(c2ccccc2)c2cc(OC)c(CNC(CC(O)=O)CC(O)=O)cc2*(C)C1 Chemical compound CCCCC1(CC)NC(c2ccccc2)c2cc(OC)c(CNC(CC(O)=O)CC(O)=O)cc2*(C)C1 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32821210P | 2010-04-27 | 2010-04-27 | |
| US61/328,212 | 2010-04-27 | ||
| US32922510P | 2010-04-29 | 2010-04-29 | |
| US61/329,225 | 2010-04-29 | ||
| PCT/US2011/034024 WO2011137135A1 (en) | 2010-04-27 | 2011-04-27 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525444A JP2013525444A (ja) | 2013-06-20 |
| JP2013525444A5 true JP2013525444A5 (enExample) | 2014-05-22 |
| JP5702853B2 JP5702853B2 (ja) | 2015-04-15 |
Family
ID=44861895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508174A Active JP5702853B2 (ja) | 2010-04-27 | 2011-04-27 | 化合物 |
Country Status (39)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| JP2014527071A (ja) | 2011-08-31 | 2014-10-09 | マリンクロッド エルエルシー | Ｈ−ホスホネートによるナノ粒子ｐｅｇの改変 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| UY35548A (es) | 2013-05-02 | 2014-11-28 | Glaxosmithkline Ip No 2 Ltd | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. |
| KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| RU2017105217A (ru) * | 2014-08-05 | 2018-09-06 | ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед | Синтез бензотиазепинов |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| ES2770123T3 (es) | 2015-02-02 | 2020-06-30 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| WO2018002827A1 (en) * | 2016-06-27 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Synthetic methods |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| EP3810084A1 (en) | 2018-06-20 | 2021-04-28 | Albireo AB | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| DK3921028T3 (da) | 2019-02-06 | 2023-01-23 | Albireo Ab | Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN118834175A (zh) | 2019-02-06 | 2024-10-25 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| JP7562546B2 (ja) | 2019-02-12 | 2024-10-07 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法 |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| DK4069360T3 (da) * | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| JP7696897B2 (ja) * | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
| PT4069360T (pt) * | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2972045T3 (es) * | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN116157389B (zh) | 2020-08-03 | 2026-02-10 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023548788A (ja) | 2020-10-20 | 2023-11-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | 胆汁うっ滞性そう痒症を治療する方法 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3205558A1 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Forms of linerixibat |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| AU2023285002A1 (en) | 2022-06-09 | 2024-12-05 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| CN121263187A (zh) | 2023-06-06 | 2026-01-02 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 回肠胆汁酸转运蛋白抑制剂用于治疗瘙痒的新用途 |
| WO2025078973A1 (en) | 2023-10-09 | 2025-04-17 | Assia Chemical Industries Ltd. | Solid state forms of linerixibat and process for preparation thereof |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370015A (en) | 1933-07-24 | 1945-02-20 | Merck & Co Inc | Derivatives of tertiary amino aliphatic acids |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (fr) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| BR0306643A (pt) | 2002-01-17 | 2004-10-19 | Pharmacia Corp | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical |
| AU2004230670B2 (en) | 2003-01-09 | 2010-11-25 | Genentech, Inc. | Purification of polypeptides |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| EP2367554A4 (en) * | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
-
2011
- 2011-04-25 JO JOP/2011/0139A patent/JO3131B1/ar active
- 2011-04-26 UY UY0001033353A patent/UY33353A/es not_active Application Discontinuation
- 2011-04-26 AR ARP110101432A patent/AR081337A1/es active IP Right Grant
- 2011-04-27 DK DK11775513.2T patent/DK2563122T3/en active
- 2011-04-27 HR HRP20161103TT patent/HRP20161103T1/hr unknown
- 2011-04-27 CA CA2795543A patent/CA2795543C/en active Active
- 2011-04-27 CN CN201180021342.6A patent/CN102858159B/zh active Active
- 2011-04-27 UA UAA201211711A patent/UA110338C2/ru unknown
- 2011-04-27 AU AU2011245393A patent/AU2011245393B2/en active Active
- 2011-04-27 PL PL11775513.2T patent/PL2563122T3/pl unknown
- 2011-04-27 ES ES11775513.2T patent/ES2588743T3/es active Active
- 2011-04-27 PH PH1/2012/502128A patent/PH12012502128B1/en unknown
- 2011-04-27 MY MYPI2012004753A patent/MY162933A/en unknown
- 2011-04-27 SG SG2012074860A patent/SG184812A1/en unknown
- 2011-04-27 MX MX2012012527A patent/MX2012012527A/es active IP Right Grant
- 2011-04-27 PT PT117755132T patent/PT2563122T/pt unknown
- 2011-04-27 ME MEP-2016-160A patent/ME02490B/me unknown
- 2011-04-27 HU HUE11775513A patent/HUE029480T2/en unknown
- 2011-04-27 MA MA35373A patent/MA34235B1/fr unknown
- 2011-04-27 RS RS20160709A patent/RS55079B1/sr unknown
- 2011-04-27 SI SI201130920A patent/SI2563122T1/sl unknown
- 2011-04-27 LT LTEP11775513.2T patent/LT2563122T/lt unknown
- 2011-04-27 EA EA201290909A patent/EA021753B1/ru not_active IP Right Cessation
- 2011-04-27 KR KR1020127030621A patent/KR101769079B1/ko active Active
- 2011-04-27 BR BR112012026767A patent/BR112012026767B1/pt active IP Right Grant
- 2011-04-27 US US13/640,166 patent/US9040518B2/en active Active
- 2011-04-27 NZ NZ602754A patent/NZ602754A/en unknown
- 2011-04-27 WO PCT/US2011/034024 patent/WO2011137135A1/en not_active Ceased
- 2011-04-27 EP EP11775513.2A patent/EP2563122B1/en active Active
- 2011-04-27 PE PE2012002082A patent/PE20130384A1/es active IP Right Grant
- 2011-04-27 JP JP2013508174A patent/JP5702853B2/ja active Active
-
2012
- 2012-09-28 CO CO12170751A patent/CO6612267A2/es active IP Right Grant
- 2012-10-04 DO DO2012000263A patent/DOP2012000263A/es unknown
- 2012-10-11 IL IL222365A patent/IL222365A/en active IP Right Grant
- 2012-10-18 ZA ZA2012/07858A patent/ZA201207858B/en unknown
- 2012-10-26 CL CL2012003009A patent/CL2012003009A1/es unknown
- 2012-11-01 CR CR20120557A patent/CR20120557A/es unknown
-
2016
- 2016-08-24 CY CY20161100830T patent/CY1118187T1/el unknown
- 2016-08-29 SM SM201600293T patent/SMT201600293B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525444A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| JP2012255026A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2012092110A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| JP2013532687A5 (enExample) | ||
| JP2012500090A5 (enExample) | ||
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| JP2015155440A5 (enExample) | ||
| JP2010525055A5 (enExample) | ||
| JP2014530840A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2013532130A5 (enExample) |